Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK-1169 vs ceftazidime-avibactam for HABP/VABP (Phase 3, China)
CTR20254968Phase 3Active
- Sponsor
- Nanjing Libowei Pharmaceutical
- Start
- Jan 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cefepime + avibactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Nanjing Libowei Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
cefepime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20254968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254968.